Genesee Valley Trust Co. lowered its position in Mead Johnson Nutrition Co. (NYSE:MJN) by 3.4% during the second quarter, Holdings Channel reports. The institutional investor owned 3,602 shares of the company’s stock after selling 125 shares during the period. Genesee Valley Trust Co.’s holdings in Mead Johnson Nutrition were worth $327,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Tobam acquired a new position in Mead Johnson Nutrition during the first quarter worth $3,021,000. CLS Investments LLC acquired a new position in Mead Johnson Nutrition during the first quarter worth $614,000. Ngam Advisors L.P. boosted its position in Mead Johnson Nutrition by 20.2% in the first quarter. Ngam Advisors L.P. now owns 116,165 shares of the company’s stock worth $9,871,000 after buying an additional 19,556 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new position in Mead Johnson Nutrition during the first quarter worth $4,605,000. Finally, Apertura Capital LLC boosted its position in Mead Johnson Nutrition by 146.2% in the first quarter. Apertura Capital LLC now owns 80,000 shares of the company’s stock worth $6,798,000 after buying an additional 47,500 shares in the last quarter. Institutional investors and hedge funds own 96.93% of the company’s stock.

Shares of Mead Johnson Nutrition Co. (NYSE:MJN) traded up 1.42% during trading on Thursday, reaching $79.25. The company had a trading volume of 1,181,439 shares. The firm has a market capitalization of $14.63 billion, a price-to-earnings ratio of 29.82 and a beta of 1.17. Mead Johnson Nutrition Co. has a 52 week low of $65.53 and a 52 week high of $94.40. The firm has a 50-day moving average of $83.30 and a 200 day moving average of $84.69.

Mead Johnson Nutrition (NYSE:MJN) last posted its earnings results on Thursday, July 28th. The company reported $0.88 EPS for the quarter, topping the Zacks’ consensus estimate of $0.78 by $0.10. The company had revenue of $941.50 million for the quarter, compared to the consensus estimate of $967.25 million. Mead Johnson Nutrition had a negative return on equity of 194.30% and a net margin of 13.28%. Mead Johnson Nutrition’s quarterly revenue was down 8.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.76 earnings per share. On average, equities research analysts forecast that Mead Johnson Nutrition Co. will post $3.49 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 3rd. Stockholders of record on Monday, September 19th will be issued a $0.4125 dividend. The ex-dividend date of this dividend is Thursday, September 15th. This represents a $1.65 dividend on an annualized basis and a dividend yield of 2.08%. Mead Johnson Nutrition’s dividend payout ratio (DPR) is 62.03%.

A number of equities analysts have recently weighed in on the company. Zacks Investment Research cut Mead Johnson Nutrition from a “hold” rating to a “sell” rating in a report on Tuesday, July 26th. JPMorgan Chase & Co. upgraded Mead Johnson Nutrition from a “neutral” rating to an “overweight” rating and set a $105.00 price target for the company in a report on Tuesday, July 26th. Deutsche Bank AG set a $88.00 price target on Mead Johnson Nutrition and gave the stock a “hold” rating in a report on Sunday, July 24th. Citigroup Inc. increased their price target on Mead Johnson Nutrition from $100.00 to $105.00 and gave the stock a “buy” rating in a report on Monday, July 25th. Finally, Goldman Sachs Group Inc. reiterated a “neutral” rating and set a $96.00 price target (up from $91.00) on shares of Mead Johnson Nutrition in a report on Friday, July 15th. One research analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $95.75.

In other news, SVP Graciela Monteagudo sold 45,873 shares of the business’s stock in a transaction on Friday, August 5th. The stock was sold at an average price of $87.64, for a total value of $4,020,309.72. Following the completion of the transaction, the senior vice president now directly owns 13,800 shares of the company’s stock, valued at $1,209,432. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Kimberly A. Casiano sold 710 shares of the business’s stock in a transaction on Monday, August 15th. The stock was sold at an average price of $89.75, for a total value of $63,722.50. Following the completion of the transaction, the director now directly owns 7,110 shares of the company’s stock, valued at $638,122.50. The disclosure for this sale can be found here. 0.50% of the stock is owned by insiders.

Mead Johnson Nutrition Company Profile

Mead Johnson Nutrition Company (Mead Johnson) is a pediatric nutrition company. The Company manufactures, distributes and sells infant formulas, children’s nutrition and other nutritional products. The Company operates through three segments: Asia, North America/Europe and Latin America. Its product portfolio includes routine and specialty infant formulas, children’s milks and milk modifiers, dietary supplements for pregnant and breastfeeding mothers, pediatric vitamins, and products for pediatric metabolic disorders.

5 Day Chart for NYSE:MJN

Want to see what other hedge funds are holding MJN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mead Johnson Nutrition Co. (NYSE:MJN).

Receive News & Ratings for Mead Johnson Nutrition Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mead Johnson Nutrition Co. and related companies with MarketBeat.com's FREE daily email newsletter.